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Between July 1987 and May 1995, 11,315 patients underwent general 
thoracic surgical procedures at our institution. In 47 of these patients 
(0.42%), postoperative chylothorax developed. There were 32 men and 15 
women with a median age of 65 years (range 21 to 88 years). Initial 
operation was for esophageal disease in 27 patients, pulmonary disease in 
13, mediastinal mass in six, and thoracic aortic aneurysm in one. All 
patients were initially treated with hyperalimentation, cessation of oral 
intake, medium chain triglyceride diet, or a combination. Nonoperative 
therapy was successful in 13 cases (27.7%), and oral intake was resumed a
median of 7 days later (range 2 to 15 days). Reoperation was required in the 
remaining 34 cases. The reoperation rate varied according to the type of 
initial operation. Twenty-four of the 27 patients (88.9%) who had under- 
gone an esophageal operation required reoperation, versus only five of 13 
patients (38.5%) who had undergone pulmonary resection (p < 0.001). 
Lymphangiography was performed in 16 patients and identified the site of 
the leak in 13. The thoracic duct was ligated in 32 of the 34 patients who 
required reoperation (94%). The remaining two patients were treated with 
mechanical pleurodesis and fibrin glue. Reoperation was successful in 31 of 
the 34 patients (91.2%). The single death among the 47 patients (2.1%) 
occurred in the reoperated group. Complications occurred in 18 patients 
(38.3%). Factors that predicted the need for reoperation were initial 
esophageal operation and average daily postoperative drainage greater 
than 1000 ml/day for 7 days. We conclude that postoperative chylothorax is
an infrequent complication. Some cases can be managed without operation; 
however, we recommend early reoperation when drainage is greater than 
1000 ml/day or if the chylous fistula occurs after an esophageal operation. 
The fistula can usually be controlled by ligation of the thoracic duct. 
(J Thorac Cardiovasc Surg 1996;112:1361-6) 
T he thoracic duct, the main tributary of the lym- phatic system, is a 2.0 to 3.0 mm thin-walled 
structure that begins at the cisterna chyli at the second 
lumbar vertebra and enters the chest through the 
aortic hiatus. It lies posterior to the aorta and courses 
to the right of the spine. It usually crosses to the left at 
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the fifth thoracic vertebra nd then ascends into the 
neck posterior to the aortic arch and empties into the 
left jugulosubclavian junction. Its proximity to the 
esophagus, presence of collateral channels, and highly 
variable course leads to its injury during esophageal 
and pulmonary resection. Injuries to the main thoracic 
duct or large tributaries rarely close spontaneously. 
We reviewed our experience with iatrogenic hylotho- 
rax after general thoracic surgical procedures to iden- 
tify factors that predict he need for reoperation and to 
evaluate the success of management. 
Patients and methods 
Between July 1987 and May 1995, 11,315 general thoracic 
surgical procedures were performed at our institution and a 
postoperative chylothorax developed in 47 patients (0.42%). 
The diagnosis was established by a triglyceride content of 110 
mg/dl or greater and the presence of chylomicrons in the 
pleural fluid in all patients. 
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Ivor Lewis esophagogastrectomy 10 
Extended Ivor Lewis esophagogastrectomy 6 
Transhiatal esophagogastrectomy 6 
Transhiatal esophagogastrectomy/total laryngectomy 2 
Esophagectomy with colonic interposition 1 
Esophageal myotomy 1 




Wedge excision 2 
Segmentectomy 1 
Pneumonectomy 1 
Sleeve pneumonectomy 1 
13 
Others 
Resection of mediastinal mass 
Repair descending thoracic aortic aneurysm 
The medical records of these 47 patients were reviewed 
for age, sex, preoperative history, operative and pathologic 
findings, amount of daily chest ube drainage, and method of 
management of the chylothorax. Lymphangiography was 
performed by direct cannulation of a lymphatic hannel in 
the dorsum of the foot after injection of Ethiodol (Altana, 
Inc., Melville, N.Y.) into the four webbed spaces on each 
foot. After cannulation of a lymphatic hannel, 1% Lym- 
phazurin (isosulfan blue; Hirsch Industries, Inc., Richmond, 
Va.) contrast was injected and serial roentgenograms were 
performed. Follow-up data were obtained from the patients' 
most recent clinic visits, home health care providers, and, 
when needed, telephone interviews. 
Patients with cancer were postsurgically staged by the 
TNM classification system of the American Joint Com- 
mittee on Cancer Staging and End Results Reporting. 1 
Operative mortality was defined as any death within 30 
days of operation or during the same hospitalization. 
Survival was estimated by the Kaplan-Meier method with 
the date of thoracotomy asthe starting time. 2 The influ- 
ences of variables on survival and morbidity were analyzed 
with the proportional hazards model of Cox 3 for contin- 
uous variables and the log-rank test for discrete variables. 4 
Values of p lower than 0.05 were considered statistically 
significant. Data are expressed as medians with ranges. 
Clinical findings 
There were 32 male and 15 female patients, with 
a median age of 65 years (range 21 to 88 years). 
Significant medical conditions were present before 
initial thoracotomy in 25 patients (53.0%) and in- 
cluded myocardial infarction in seven, hypertension 
in five, chronic obstructive pulmonary disease in 
four, lymphoma in three, diabetes mellitus in two, 
and atrial fibrillation, colon cancer, breast cancer, 
and lung cancer in one each. Three patients had 
previous contralateral thoracotomy and two had 
previous ipsilateral thoracotomy. The indications 
for the five previous thoracotomies were pulmonary 
metastases in two patients and gastroesophageal 
reflux, empyema thoracis, and lung cancer in one 
patient each. Preoperative radiation therapy was 
administered to six patients, and five received pre- 
operative chemotherapy. 
The initial operations were performed for esoph- 
ageal cancer in 23 patients, lung cancer in 10, 
mediastinal mass in six, pulmonary metastases in 
two, reflux esophagitis in two, benign esophageal 
stricture in two, and achalasia and thoracic aortic 
aneurysm in one each. 
Results 
The initial procedures performed are shown in 
Table I. Esophageal operations were performed in 27 
patients, pulmonary in operations were performed 13, 
and other operations were performed in seven. 
All patients had thoracostomy tubes after their 
initial operation. Two patients who had a pneumo- 
nectomy had the chest tube removed immediately 
after skin closure in the operating room. Chylotho- 
rax was diagnosed a median of 5 days after opera- 
tion (range 3 to 82 days). The chylothorax was on 
the right side in 34 patients, on the left side in nine, 
and bilateral in four. The mean triglyceride content 
of the drainage was 370 mg/dl (range 118 to 2416 
mg/dl), and the mean cholesterol content of the 
fluid was 48 mg/dl (range 19 to 97 mg/dl). All 
patients had chylomicrons in their chest drainage. 
The median daily chest drainage for the first 7 
postoperative days was 1117 ml (range 286 to 2225 
ml). All patients were initially treated by dietary 
manipulation. This included complete cessation of 
oral intake and central hyperalimentation i  36 
patients and a medium-chain triglyceride diet in 11 
patients. This treatment was successful for seven 
patients who received total parenteral nutrition and 
in six patients who received medium-chain triglycer- 
ide diets. These patients resumed a normal diet a 
median of 7 days after the diagnosis of chylothorax 
was made (range 2 to 15 days). The remaining 34 
patients (72.3%) required reoperation to control the 
fistula. The median daily chest drainage for the first 
7 postoperative days was 1168 ml in the group that 
required reoperation and 511 ml for the patients 
who did not require reoperation (Fig. 1). Addition- 
ally, 24 of the 27 patients in whom the chylothorax 
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Fig. 1. Comparison of median daily thoracostomy tube output of 34 patients who required reoperation 
and 13 patients who did not. Median daily thoracostomy output was statistically significantly different 
between these two groups (p = 0.0001). 
occurred after esophageal operations (88.9%) re- 
quired reoperation tocontrol the fistula; only five of 
13 who had chylothorax after pulmonary resections 
(38.5%) required reoperation (p < 0.001). Lym- 
phangiography was performed in 16 patients before 
reoperation and a leak was identified in 13 (81.3%). 
In these 13 patients, reoperation confirmed this area 
to be the site of the fistula. 
Reoperation was undertaken a median of 9 days 
after operation (range, 4 to 106 days). The reopera- 
tion was performed on the side of the chylothorax in
28 patients and on the contralateral side in six. The 
approach for the reoperation was through the initial 
thoracotomy in 28 patients, through anew thoracot- 
omy in three, and by video-assisted thoracic surgery 
in three. Two of the patients who underwent video- 
assisted thoracoscopic surgery had the procedure 
converted to thoracotomy because of inability to 
visualize the duct. The injury to the thoracic duct 
was identified at reoperation i 23 of the 34 patients 
(67.6%) and was at the level of the diaphragm in 11, 
the azygos vein in nine, and the apex of the chest in 
three. 
The thoracic duct was ligated in 32 of the 34 
patients. The site of ligation was the diaphragm in 
13 patients, immediately below the fistula in 12, and 
both sites in seven. In addition, mechanical pleu- 
rodesis was performed in 16, talc pleurodesis was 
performed in three, and a partial parietal pleurec- 
tomy was performed in three. The two patients that 
did not have the thoracic duct ligated underwent 
mechanical pleurodesis and had fibrin glue applied 
to the posterior mediastinum. The fistula was suc- 
cessfully controlled in 31 patients (91.2%). Three 
patients required a second reoperation because of 
continued leakage of chyle; the second reoperation 
was successful in all three cases. Table II illustrates 
the management of these cases. 
There was one death among the 47 patients (2.1%). 
This death was that of a 70-year-old man with severe 
chronic obstructive pulmonary disease who underwent 
a transhiatal esophagectomy for T3NoM 0 squamous 
cell cancer of the esophagus. He had a left thoracot- 
omy for chylothorax on postoperative day 8. Pneumo- 
nia developed, and he died of sepsis and adult respi- 
ratory distress yndrome. Complications occurred in 
18 patients (38.3%): atrial fibrillation in 12, prolonged 
ventilation in three, and prolonged air leak, cervical 
anastomotic leak, and respiratory failure necessitating 
tracheostomy in one each. 
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Table II. Management of three patients who had 
multiple reoperations to control chylothorax 
Initial reoperation Second reoperation 
1 Ligated duct at diaphragm Religated uct at dia- 
and fibrin glue applied to phragm, pleureetomy, 
mediastinum and fibrin glue applied to 
mediastinum 
2 Ligated duct at level of azy- Ligated duct in abdomen 
gos vein and talc pleu- via laparotomy 
rodesis 
3 Ligated duct at diaphragm Ligated accessory thoracic 
duct 
Discussion 
Chylothorax is uncommon after thoracic surgical 
procedures. In our review, we found only 47 patients 
with chylothorax out of 11,315 who underwent a
general thoracic surgical procedure at our institu- 
tion (0.42%). Although chylothorax has been re- 
ported after almost every type of thoracic operation, 
certain patients may be predisposed toward postop- 
erative chylothorax. Esophageal resections for car- 
cinoma with mediastinal lymphadenectomy ay 
lead to a higher incidence of postoperative chylo- 
thorax. Among our patients, the overall incidence of 
chylothorax was 0.42%; after esophagectomy, how- 
ever, it was 2.9%. In contrast, our incidence of 
postpneumonectomy ch lothorax was much lower 
(0.37%) and compares favorably with that reported 
by Vallieres, Shamji, and Todd 5 in 1993. Our inci- 
dence of chylothorax after lobectomy was 0.26%. 
We believe that intraoperative prevention is impor- 
tant. If the thoracic duct is suspected to have been 
damaged during a thoracic procedure, ligation, 
pleurodesis, orboth should be performed to prevent 
subsequent chylothorax. 
Injury to the thoracic duct should be suspected 
when unexplained high thoracostomy tube drainage 
is present after operation. The fluid may not be 
"milky white" if the patient is not taking anything by 
mouth. The diagnosis of chylothorax is established 
by examination of pleural fluid. Both chylomicrons 
and a triglyceride concentration greater than 110 
mg/dl are diagnostic of chylothorax. After pneumo- 
nectomy, the diagnosis i more difficult because fluid 
normally fills the postpneumonectomy space. How- 
ever, patients with a chylothorax after pneumonec- 
tomy often have a shift of the mediastinum to the 
contralateral side because of continued infusion. If 
chylothorax is suspected, thoracentesis should be 
performed to establish the diagnosis. 
The electrolyte content of chyle is similar to that 
of serum. 6Because the thoracic duct transports 60% 
to 70% of ingested fat to the blood stream, the usual 
concentration f fat in chyle is 0.4 to 6.0 gm/dl. The 
concentration f protein in chyle is 2.2 to 6.0 gm/dl. 7 
Chyle also contains from 400 to 6800 white blood 
cells/ml. 
The thoracic duct flow increases after meals, 
especially when a high-fat meal is ingested. Flow 
rates as high as 110 ml/hr have been recorded. 7 
From 2 to 3 L chyle, with its associated proteins, 
white blood cells, and electrolytes, can be lost daily 
from a thoracic duct fistula. Consequently, a pro- 
longed chyle fistula is poorly tolerated and is asso- 
ciated with significant mortality if not corrected. 
Because starvation usually reduces the flow of 
chyle, all of our patients had complete cessation of 
oral intake after a chylous fistula was diagnosed. In 
selected patients, a medium-chain triglyceride diet 
also may be successful. The theory behind a 
medium-chain triglyceride diet as a treatment for 
chylous fistula was described in 1964 by Hashim and 
colleagues. 8 These triglycerides contain fatty acids 
with a chain length of fewer than 12 carbon atoms 
and are absorbed into the portal vein and trans- 
ported directly to the liver, where they are metabo- 
lized. Six of our 11 patients who were placed on a 
medium-chain triglyceride diet had resolution of 
their chylothorax. 
If nonoperative therapy with cessation of oral 
intake or a medium-chain triglyceride diet is unsuc- 
cessful, reoperation should be considered. Identifi- 
cation of the site of the chyle leak can help to 
determine the surgical approach, allowing the sur- 
geon to look in a specific area. Lymphangiography 
successfully located the leak in 81% of our patients. 
In addition, lymphangiography can demonstrate ac- 
cessory ducts and the course of the main duct. None 
of our patients had pulmonary dysfunction as a 
result of lymphangiography, as was reported by 
Rosenow, Wilson, and Cockerill. 9
Other methods that may help identify the site of 
leak at operation include feeding the patient a 
high-fat diet several hours before operation. This 
will increase the flow of chyle and can assist the 
surgeon in identifying the leak. In 1955, Merrill 1° 
described injection of Evans blue dye subcutane- 
ously in the thigh for prompt intraoperative identi- 
fication of the thoracic duct. A year later, Stranahan 
and colleagues n described intraoperative ductogra- 
phy to aid in identifying the fistula. Neither of these 
latter techniques was employed in any of our cases. 
The decision of when to reoperate is important. 
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We found that chest thoracostomy drainage greater 
than 1000 ml/day for the first 7 days and the 
development of a chylothorax after an esophageal 
operation were significant factors that predicted the 
need for reoperation. Others have reported similar 
findings. 12 Patterson and coworkers 13 recommended 
observation for 7 days; if drainage was still greater 
than 1000 ml/day, reoperation to ligate the thoracic 
duct was necessary. If drainage is high or chylotho- 
rax occurs after an esophageal operation, early 
reoperation should be strongly considered. 
The reoperative approach is another important 
decision. In most of our patients with a previous 
thoracotomy, the chylothorax was on the ipsilateral 
side and the reoperation was through the original 
thoracotomy. If lymphangiography demonstrates 
that the thoracic duct is only accessible from the 
contralateral side, however, a contralateral thora- 
cotomy should be performed. 
When the reoperation is performed on the side of 
the chylothorax, pleurodesis or pleurectomy should 
also be performed at the same time as thoracic duct 
ligation. If the thoracic duct is ligated contralateral 
to the effusion, pleurodesis or pleurectomy is not 
necessary. 
In most of our patients, the thoracic duct was 
ligated at the diaphragmatic level, as suggested by 
Murphy and Piper 14 in 1977. Ligation at this level 
has the advantage of stopping flow from any acces- 
sory ducts that may not be recognized. If the tho- 
racic duct cannot be found or if ligation does not 
control the leak, pleurodesis is indicated. Other 
methods to control chylothorax described in the 
literature include radiation therapy, phrenic nerve 
crush, and reimplantation of the thoracic duct into a 
vein or reanastomosis of a torn thoracic duct. 5 
Finally, a pleural-peritoneal shunt can be used to 
transport chyle into the abdomen or a pleural- 
venous shunt can be employed to reinfuse chyle into 
the venous system. Readministration of  aspirated 
chyle by mouth or rectum has been tried but has not 
been found to be of benefit. None of these alterna- 
tive techniques were used in our patients. 
Chylothorax is an infrequent postoperative com- 
plication. Although chylothorax can occasionally be 
treated by nonoperative therapy, when chest thora- 
costomy drainage is greater than 1000 ml/day or 
chylothorax occurs after an esophageal operation, 
surgical intervention will probably be necessary. 
Lymphangiography can help locate the fistula and 
determine the course of  the thoracic duct. The 
fistula can usually be controlled by ligation at the 
diaphragm or at the site of the fistula. Pleurodesis 
may also be necessary. 
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Discussion 
Dr. George T. Christakis (Toronto, Ontario, Canada). 
Congratulations, on a well-presented and well-thought 
out article. This is an important study because it expands 
the surgeon's knowledge and understanding of an uncom- 
mon complication after thoracic surgery. 
Current trends in the epidemiology of disease have 
underscored the necessity of using evidence-based medi- 
cine when producing conclusions or recommendations 
from studies. This would normally impose the need for a 
prospective randomized trial to reasonably answer any 
questions. In the case of rare postoperative outcomes, 
such as the incidence of chylothorax following thoracic 
surgery, a randomized control trial would require the 
enrollment of many thousands of patients and would be 
practically impossible. This represents the logic for my 
praise, and for soliciting further presentations that ad- 
dress rare perioperative complications. 
On the basis of this large experience from the Mayo 
Clinic, I would like to ask the following questions. First, 
patients undergoing operations for esophageal cancer 
have a limited long-term survival, and the major indica- 
tion for surgery is improvement of the quality of life. 
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Because you have clearly demonstrated that 89% of 
patients with chylothorax after esophageal surgery even- 
tually require repair, why extend costly hospital stay by 
treating these patients with hyperalimentation? Why not 
recommend immediate operation on discovering chylo- 
thorax? This would expedite recovery and minimize hos- 
pital stay, so that patients would be able to live whatever 
life they had left outside of hospital. 
Second, medium-chain triglyceride diets appeared to 
have a high success rate, certainly higher than parenteral 
nutrition in this study. What were the indications for 
prescribing a medium-chain triglyceride diet, and why do 
you not recommend that all patients with chylothorax be 
given such a diet? 
Finally, lymphangiograms also appeared to be very 
successful in identifying the site of the leak in 13 of 16 
patients in your study. Why were lymphangiograms not 
performed routinely for all patients, especially because 
this test may find a leak in the contralateral side of the 
chest? 
Dr. Cerfolio. We recommend waiting 1 week before 
reoperation i patients with chylothorax after esophageal 
resection for several reasons. First, the diagnosis of chy- 
lothorax is usually not made until approximately 4 or 5 
days after operation. It is only suspected in the first few 
postoperative days because of unexplained high chest ube 
drainage. It then takes a few more days for the lipid 
analysis to confirm the diagnosis. Because we have shown 
that there is about 10% success with medical treatment, 
we believe a medical trial of a few days is warranted, 
especially in patients with drainage of 1000 ml or less. 
Furthermore, a few days gives the patients time to both 
prepare physically and mentally for reoperation. Past 
literature has shown that a 3- to six-week delay is associ- 
ated with significant morbidity, but we do not believe that 
this is true of a 2- to 3-day delay. 
Your second question concerned medium-chain triglyc- 
eride diet. We had 11 patients who received medium- 
chain triglyceride diets and 34 who got total parenteral 
nutrition. As you know, this is a retrospective study. Seven 
of 11 patients who received medium-chain triglyceride 
diets did not have esophageal resections, they had pulmo- 
nary resections, and they had drainage that was on 
average lower than that of the patients who received total 
parenteral nutrition. The success rate may have been 
higher for patients receiving medium-chain triglyceride 
diets because of patient selection. We do not believe that 
the medium-chain triglyceride diet is superior to total 
parenteral nutrition. 
Your third question concerned lymphangiography. 
There are four thoracic surgeons at the Mayo Clinic, and 
they all have different practices. One surgeon routinely 
uses lymphangiography for patients with postoperative 
chylothorax, and he has found it to be valuable; however, 
he has not quite persuaded the other three. I believe that 
this article does offer evidence that lymphangiography is a
valuable test. It helps to identify accessory ducts, which 
are not always controlled when the main thoracic duct is 
ligated. Second, and very important, it identifies the main 
thoracic duct and guides the surgeon's reoperative ap- 
proach for ligation. 
Dr. Joseph I. Miller (Atlanta, Ga.). While I was at the 
Mayo Clinic, O. T. Clagett stated that if you had a 
postoperative thoracic duct fistula you could radiate the 
thoracic duct to 2000 rads. In my 23 years at Emory, we 
have had four such cases, two after an Ivor Lewis esopha- 
gogastrectomy and one right pneumonectomy and one left 
upper lobectomy. We added 2000 rads after operation, 
and they all stopped. I know of six other cases in the 
southern region in which the fistula, stopped, as Clagett's 
advice suggests. Only in the case of malignant disease, but 
you can radiate the thoracic duct to about 2000 to 2500 
rads and they all stop without reoperation. 
Dr. Cerfolio. We do mention some of the alternative 
treatments for chylothorax in the article. We believe that 
there is a role for some of these in selected patients. In 
patients with benign disease, radiation would probably be 
a poor choice. We appreciate your bringing up the option 
of radiation for patients with malignant disease. 
Dr. Anthony L. Moulton (Providence, R.L). Just a 
couple of questions. In terms of the esophageal disease, 
did you see a difference in the incidence of chylothorax 
between patients who underwent a transhiatal resection 
and those who underwent an Ivor Lewis resection? What 
was the effect of the extent of the nodal dissection as well? 
Recently we have been involved with a number of 
patients who have received preoperative paclitaxel 
(Taxol) and irradiation. In those patients, we have found 
an incredible inflammatory response with massive lymph- 
adenopathy. We have felt obligated to resect all of that to 
make sure that there was no residual tumor. It is our 
impression that we have seen an increased incidence of 
chylothorax after this extensive dissection. Do you have 
any comments about the incidence of chylothorax in 
patients who received neoadjuvant therapy before opera- 
tion? 
Dr. Cerfolio. Those are important questions that we did 
statistically analyze. Because of the small numbers in this 
series, we cannot say that one type of esophageal resection 
had a higher incidence of postoperative chylothorax than 
another. Also, we found no statistically significant differ- 
ence between patients with positive lymph nodes versus 
those with negative lymph nodes. One would need to 
analyze all patients who underwent esophagogastrectomy, 
however, and compare the incidences of postoperative 
chylothorax among the patients with positive lymph nodes 
and those with negative lymph nodes to accurately answer 
your question. 
At the Mayo Clinic, the general philosophy is to do a 
rather large resection of tissue around the esophagus, and 
oftentimes the thoracic duct is seen during operation. If 
the duct is seen at the time of initial esophageal resection, 
it is prophylactically igated at the level of the diaphragm. 
